Low-dose dapagliflozin linked to better heart failure outcomes
In a 96-week trial subanalysis, dapagliflozin 5 mg ranked better in 19.34% of patient-pair comparisons, versus 5.04% for control.
Multicenter
Limit: This after-the-fact analysis included selected participants from an open-label trial
Edited by Boris Djordjevic · AgingResearch.News
The analysis compared 128 people with type 2 diabetes and chronic heart failure who took dapagliflozin 5 mg throughout the study with 138 control patients. It was a secondary analysis of a randomized, open-label trial, meaning patients and researchers knew the assigned groups. Follow-up lasted 96 weeks.
Researchers compared pairs of patients using a ranked measure of death from cardiovascular causes, the number of heart failure hospitalizations, time to the first hospitalization and increases in heart failure medicines. Dapagliflozin was associated with better results on this combined measure. The analysis also linked dapagliflozin to fewer heart failure hospitalizations and less escalation of heart failure medicines.
Why it matters
For heart failure, an age-related disease, the study addresses the limited evidence for a lower dapagliflozin dose in people who also have type 2 diabetes.
Caveats
This after-the-fact analysis included selected participants from an open-label trial. The conference abstract reported no safety results, and the findings do not establish benefits for people without both type 2 diabetes and chronic heart failure.
The paper
National Cerebral and Cardiovascular Center; Hanwa Memorial Hospital
ESC Congress 2026 Abstract, Oct 26, 2026
Presented at ESC Congress 2026